onr:"swepub:oai:gup.ub.gu.se/320501"
Search: onr:"swepub:oai:gup.ub.gu.se/320501" > Societal costs of o...
- 1 of 1
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04865naa a2200541 4500 | |
| 001 | oai:gup.ub.gu.se/320501 | |
| 003 | SwePub | |
| 008 | 240528s2022 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/3205012 URI |
| 024 | 7 | a https://doi.org/10.1080/0284186x.2022.21400152 DOI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Palmqvist, Charlotteu Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology4 aut |
| 245 | 1 0 | a Societal costs of ovarian cancer in a population-based cohort - a cost of illness analysis |
| 264 | c 2022-11-03 | |
| 264 | 1 | b Informa UK Limited,c 2022 |
| 520 | a Background The societal cost associated with ovarian cancer (OC) is not well known. Increasing costs for new treatments and/or the impact of organizational changes motivates these costs to be described and communicated. This study aims to evaluate the cost of illness of OC in a population-based cohort. Material and methods All patients diagnosed with ovarian, fallopian tube, primary peritoneal cancer, and serous cancer of undesignated primary site (UPS) in 2011-2012 were followed for six years. Direct costs, i.e., costs for health care expenditures, were gathered from the regional healthcare database. Information on indirect costs, i.e., costs of loss of production due to sick leave, was retrieved from Statistics Sweden. Sub-group analyses were conducted regarding stage, income levels, residential area, and diagnosis. Results The cost of illness for all stages during the six years of follow-up was euro201,086 per patient, where indirect costs constituted 43.7%. The mean cost of illness per year per patient for all stages was euro33,514. Direct costs were higher in advanced stages compared to early stages for every year from diagnosis. During the first two years, there were no differences in indirect costs between early and advanced stages. However, during the third year there was a difference with higher indirect costs in advanced stages. There was no difference in direct costs depending on income levels. Regarding residential area, there was a difference in the outpatient cost during the index and second year with higher costs when chemotherapy and follow-up were provided at county hospitals, compared to at the tertiary hospital. Conclusions Indirect costs constituted a large part of the cost of illness over 6 years from diagnosis. This could indicate that even though treatment costs can be expected to rise with the introduction of new therapies, the societal cost may decrease when survival increase. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a Cost of illness | |
| 653 | a direct cost | |
| 653 | a indirect cost | |
| 653 | a societal cost | |
| 653 | a ovarian | |
| 653 | a cancer | |
| 653 | a maintenance therapy | |
| 653 | a complete cytoreduction | |
| 653 | a niraparib maintenance | |
| 653 | a parp | |
| 653 | a inhibitors | |
| 653 | a survival | |
| 653 | a disparities | |
| 653 | a bevacizumab | |
| 653 | a guidelines | |
| 653 | a adherence | |
| 653 | a olaparib | |
| 653 | a Oncology | |
| 700 | 1 | a Persson, Josefine,d 1981u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine4 aut0 (Swepub:gu)xpejos |
| 700 | 1 | a Albertsson, Per,d 1964u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xalbpe |
| 700 | 1 | a Dahm-Kähler, Pernilla,d 1964u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology4 aut0 (Swepub:gu)xdahmp |
| 700 | 1 | a Johansson, Mia,d 1977u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xjmiaa |
| 710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi4 org |
| 773 | 0 | t Acta Oncologicad : Informa UK Limitedg 61:11, s. 1369-1376q 61:11<1369-1376x 0284-186Xx 1651-226X |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/320501 |
| 856 | 4 8 | u https://doi.org/10.1080/0284186x.2022.2140015 |
Find in a library
- Acta Oncologica (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Palmqvist, Charl ...
- Persson, Josefin ...
- Albertsson, Per, ...
- Dahm-Kähler, Per ...
- Johansson, Mia, ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Acta Oncologica
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
